S&P 500   4,356.45
DOW   34,297.73
QQQ   345.11
S&P 500   4,356.45
DOW   34,297.73
QQQ   345.11
S&P 500   4,356.45
DOW   34,297.73
QQQ   345.11
S&P 500   4,356.45
DOW   34,297.73
QQQ   345.11

Karyopharm Therapeutics Stock Forecast, Price & News

+0.05 (+0.59%)
(As of 01/25/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
2.57 million shs
Average Volume
2.16 million shs
Market Capitalization
$648.19 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive KPTI News and Ratings via Email

Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Karyopharm Therapeutics logo

About Karyopharm Therapeutics

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$108.08 million
Book Value
$0.69 per share


Net Income
$-196.27 million
Net Margins
Pretax Margin




Free Float
Market Cap
$648.19 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.41 out of 5 stars

Medical Sector

191st out of 1,416 stocks

Pharmaceutical Preparations Industry

81st out of 684 stocks

Analyst Opinion: 3.1Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

Karyopharm Therapeutics (NASDAQ:KPTI) Frequently Asked Questions

Is Karyopharm Therapeutics a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Karyopharm Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KPTI, but not buy additional shares or sell existing shares.
View analyst ratings for Karyopharm Therapeutics
or view top-rated stocks.

How has Karyopharm Therapeutics' stock been impacted by Coronavirus?

Karyopharm Therapeutics' stock was trading at $21.24 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, KPTI stock has decreased by 59.6% and is now trading at $8.58.
View which stocks have been most impacted by COVID-19

When is Karyopharm Therapeutics' next earnings date?

Karyopharm Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for Karyopharm Therapeutics

How were Karyopharm Therapeutics' earnings last quarter?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) issued its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by $0.01. The company had revenue of $37.69 million for the quarter, compared to analysts' expectations of $25.84 million. Karyopharm Therapeutics had a negative net margin of 173.81% and a negative trailing twelve-month return on equity of 7,204.16%. During the same period in the previous year, the firm earned ($0.73) EPS.
View Karyopharm Therapeutics' earnings history

What price target have analysts set for KPTI?

7 brokers have issued 1-year price objectives for Karyopharm Therapeutics' stock. Their forecasts range from $8.00 to $26.00. On average, they expect Karyopharm Therapeutics' stock price to reach $15.33 in the next twelve months. This suggests a possible upside of 78.7% from the stock's current price.
View analysts' price targets for Karyopharm Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Karyopharm Therapeutics' key executives?

Karyopharm Therapeutics' management team includes the following people:
  • Richard A. Paulson, President, CEO & Non-Executive Director
  • Ronit Milstein, Vice President-Operations
  • Mike Mason, Treasurer, Chief Financial & Accounting Officer
  • Sharon Shacham, Chief Scientific Officer
  • Yosef Landesman, Senior VP-Research & Translational Medicine

What is Michael Kauffman's approval rating as Karyopharm Therapeutics' CEO?

31 employees have rated Karyopharm Therapeutics CEO Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among Karyopharm Therapeutics' employees.

What other stocks do shareholders of Karyopharm Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY).

What is Karyopharm Therapeutics' stock symbol?

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Who are Karyopharm Therapeutics' major shareholders?

Karyopharm Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Frontier Capital Management Co. LLC (2.23%), Patriot Financial Group Insurance Agency LLC (0.05%) and Belvedere Trading LLC (0.00%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Garen G Bohlin, Jatin Shah, John Demaree, Mansoor Raza Mirza, Michael Kauffman, Ran Frenkel, Sharon Shacham, Stephen Mitchener and Tanya Lewis.
View institutional ownership trends for Karyopharm Therapeutics

Which institutional investors are buying Karyopharm Therapeutics stock?

KPTI stock was purchased by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Patriot Financial Group Insurance Agency LLC, and Belvedere Trading LLC. Company insiders that have bought Karyopharm Therapeutics stock in the last two years include Garen G Bohlin, Jatin Shah, and John Demaree.
View insider buying and selling activity for Karyopharm Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Karyopharm Therapeutics?

Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Karyopharm Therapeutics' stock price today?

One share of KPTI stock can currently be purchased for approximately $8.58.

How much money does Karyopharm Therapeutics make?

Karyopharm Therapeutics has a market capitalization of $648.19 million and generates $108.08 million in revenue each year. The company earns $-196.27 million in net income (profit) each year or ($2.76) on an earnings per share basis.

How many employees does Karyopharm Therapeutics have?

Karyopharm Therapeutics employs 432 workers across the globe.

What is Karyopharm Therapeutics' official website?

The official website for Karyopharm Therapeutics is www.karyopharm.com.

Where are Karyopharm Therapeutics' headquarters?

Karyopharm Therapeutics is headquartered at 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459.

How can I contact Karyopharm Therapeutics?

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at (617) 658-0600 or via email at [email protected].

This page was last updated on 1/26/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.